-
公开(公告)号：US20090155271A1
公开(公告)日：2009-06-18
申请号：US12370309
申请日：2009-02-12
申请人： STEVEN D. LEVIN , MARK W. RIXON , ZEREN GAO
发明人： STEVEN D. LEVIN , MARK W. RIXON , ZEREN GAO
IPC分类号： A61K39/395 , C07K14/00 , C07K16/18 , C12N15/11 , C12N15/00 , C12N5/06 , C12P21/02 , A61K38/16
CPC分类号： C07K14/54 , A61K38/00 , A61K2039/505 , C07K16/2866 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/30 , C12P21/02 , Y02A50/401
摘要： The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RA is a receptor for IL-17A and IL-17RC is a common receptor for both IL-17A and IL-17F. The present invention includes soluble IL-17A and IL-17F anatagonists, as well as methods for using the same.
摘要翻译： 本发明涉及IL-17A和IL-17F的拮抗剂。 本发明的拮抗剂单独使用IL-17RC或IL-17RC和IL-17RA（“IL-17RC / IL-17RA”）。 这种拮抗剂用于阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 IL-17RA是IL-17A的受体，IL-17RC是IL-17A和IL-17F的常见受体。 本发明包括可溶性IL-17A和IL-17F拮抗剂，以及使用它们的方法。
-
公开(公告)号：US20110014656A1
公开(公告)日：2011-01-20
申请号：US12828041
申请日：2010-06-30
申请人： STEVEN D. LEVIN , MARK W. RIXON , GAO ZEREN
发明人： STEVEN D. LEVIN , MARK W. RIXON , GAO ZEREN
CPC分类号： C07K14/7155 , A61K2039/505 , C07K16/2866 , C07K2317/73 , C07K2317/76 , C07K2319/30 , C07K2319/32
摘要： Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.
摘要翻译： 公开了IL-17A和IL-17F的拮抗剂。 拮抗剂基于可溶性IL-17RA和IL-17RC融合蛋白，包括包含IL-17RC和IL-17RA（“IL-17RC / IL-17RA”）部分的杂合可溶性受体。 这种拮抗剂用于阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者的活性。 还公开了使用这种拮抗剂治疗疾病，特别是至少部分地由IL-17A和/或IL-17F介导的炎性疾病的方法。
-
公开(公告)号：US20100130728A1
公开(公告)日：2010-05-27
申请号：US12612288
申请日：2009-11-04
申请人： MARK W. RIXON , JANE A. GROSS
发明人： MARK W. RIXON , JANE A. GROSS
IPC分类号： C07K16/00
CPC分类号： C07K16/241 , A61K38/00 , A61K39/3955 , A61K45/06 , C07K14/70578 , C07K2319/00 , C07K2319/30
摘要： Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
-
公开(公告)号：US20130171130A1
公开(公告)日：2013-07-04
申请号：US13525466
申请日：2012-06-18
申请人： DONALD C. FOSTER , WENFENG XU , KAREN L. MADDEN , JAMES D. KELLY , CINDY A. SPRECHER , CAMERON S. BRANDT , MARK W. RIXON , SCOTT R. PRESNELL , BRIAN A. FOX
发明人： DONALD C. FOSTER , WENFENG XU , KAREN L. MADDEN , JAMES D. KELLY , CINDY A. SPRECHER , CAMERON S. BRANDT , MARK W. RIXON , SCOTT R. PRESNELL , BRIAN A. FOX
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K38/00 , C07K14/7155 , C07K2319/00
摘要： A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
摘要翻译： 具有两个多肽亚单位IL-20RA（以前称为ZcytoR7）和IL-20RB（以前称为DIRS1）的IL-20的可溶性受体。 两个亚基优选连接在一起。 在一个实施方案中，一个亚基与免疫球蛋白的轻链的恒定区融合，另一个亚基与免疫球蛋白的重链的恒定区融合。 轻链和重链通过二硫键连接。
-
-
-
搜索结果
4 条记录 (耗时 0.024 秒)